S&P 500   3,931.01 (-0.26%)
DOW   33,570.24 (-0.08%)
QQQ   279.70 (-0.70%)
AAPL   140.02 (-2.02%)
MSFT   243.87 (-0.51%)
META   113.72 (-0.35%)
GOOGL   94.77 (-2.28%)
AMZN   88.30 (+0.06%)
TSLA   172.32 (-4.17%)
NVDA   160.36 (+0.31%)
NIO   12.61 (-4.76%)
BABA   88.85 (-2.84%)
AMD   69.98 (-0.41%)
T   19.25 (+0.42%)
MU   53.66 (-0.04%)
CGC   3.25 (-9.97%)
F   13.12 (-1.20%)
GE   84.99 (-0.34%)
DIS   92.09 (-0.22%)
AMC   6.07 (-10.07%)
PYPL   74.16 (+2.67%)
PFE   50.25 (+1.09%)
NFLX   306.72 (+0.38%)
S&P 500   3,931.01 (-0.26%)
DOW   33,570.24 (-0.08%)
QQQ   279.70 (-0.70%)
AAPL   140.02 (-2.02%)
MSFT   243.87 (-0.51%)
META   113.72 (-0.35%)
GOOGL   94.77 (-2.28%)
AMZN   88.30 (+0.06%)
TSLA   172.32 (-4.17%)
NVDA   160.36 (+0.31%)
NIO   12.61 (-4.76%)
BABA   88.85 (-2.84%)
AMD   69.98 (-0.41%)
T   19.25 (+0.42%)
MU   53.66 (-0.04%)
CGC   3.25 (-9.97%)
F   13.12 (-1.20%)
GE   84.99 (-0.34%)
DIS   92.09 (-0.22%)
AMC   6.07 (-10.07%)
PYPL   74.16 (+2.67%)
PFE   50.25 (+1.09%)
NFLX   306.72 (+0.38%)
S&P 500   3,931.01 (-0.26%)
DOW   33,570.24 (-0.08%)
QQQ   279.70 (-0.70%)
AAPL   140.02 (-2.02%)
MSFT   243.87 (-0.51%)
META   113.72 (-0.35%)
GOOGL   94.77 (-2.28%)
AMZN   88.30 (+0.06%)
TSLA   172.32 (-4.17%)
NVDA   160.36 (+0.31%)
NIO   12.61 (-4.76%)
BABA   88.85 (-2.84%)
AMD   69.98 (-0.41%)
T   19.25 (+0.42%)
MU   53.66 (-0.04%)
CGC   3.25 (-9.97%)
F   13.12 (-1.20%)
GE   84.99 (-0.34%)
DIS   92.09 (-0.22%)
AMC   6.07 (-10.07%)
PYPL   74.16 (+2.67%)
PFE   50.25 (+1.09%)
NFLX   306.72 (+0.38%)
S&P 500   3,931.01 (-0.26%)
DOW   33,570.24 (-0.08%)
QQQ   279.70 (-0.70%)
AAPL   140.02 (-2.02%)
MSFT   243.87 (-0.51%)
META   113.72 (-0.35%)
GOOGL   94.77 (-2.28%)
AMZN   88.30 (+0.06%)
TSLA   172.32 (-4.17%)
NVDA   160.36 (+0.31%)
NIO   12.61 (-4.76%)
BABA   88.85 (-2.84%)
AMD   69.98 (-0.41%)
T   19.25 (+0.42%)
MU   53.66 (-0.04%)
CGC   3.25 (-9.97%)
F   13.12 (-1.20%)
GE   84.99 (-0.34%)
DIS   92.09 (-0.22%)
AMC   6.07 (-10.07%)
PYPL   74.16 (+2.67%)
PFE   50.25 (+1.09%)
NFLX   306.72 (+0.38%)
OTCMKTS:ESALY

Eisai - ESALY Stock Forecast, Price & News

$70.39
-2.47 (-3.39%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$70.23
▼
$71.52
50-Day Range
$39.79
▼
$72.86
52-Week Range
$36.88
▼
$73.90
Volume
10,228 shs
Average Volume
30,393 shs
Market Capitalization
$20.19 billion
P/E Ratio
80.91
Dividend Yield
1.21%
Price Target
N/A

Eisai MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-20.53%
From $1.51 to $1.20 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.47 out of 5 stars

See Top Rated MarketRank™ Stocks Here
ESALY stock logo

About Eisai (OTCMKTS:ESALY) Stock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Receive ESALY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

ESALY Stock News Headlines

November 30, 2022 | finance.yahoo.com
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
November 30, 2022 | seekingalpha.com
Biogen rallies Alzheimer’s drug developers after full data for lecanemab
November 30, 2022 | finance.yahoo.com
Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's
November 30, 2022 | seekingalpha.com
Biogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swelling
November 30, 2022 | barrons.com
Biogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.
November 28, 2022 | seekingalpha.com
Biogen drops after report on second death linked to Alzheimer’s candidate
November 28, 2022 | finance.yahoo.com
UTHR vs. ESALY: Which Stock Is the Better Value Option?
November 17, 2022 | msn.com
After Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?
November 15, 2022 | finance.yahoo.com
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
October 29, 2022 | msn.com
Patient Death in Alzheimer's Study May Limit Drug's Reach
October 18, 2022 | seekingalpha.com
Biogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executive
October 18, 2022 | finance.yahoo.com
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
September 29, 2022 | investing.com
Biogen shares soar on landmark Alzheimer's data, lift rivals
September 28, 2022 | seekingalpha.com
Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data
September 28, 2022 | finance.yahoo.com
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022 | markets.businessinsider.com
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
September 28, 2022 | investing.com
Analysis-Alzheimer's drug breakthrough big boost for Roche, Eli Lilly
September 28, 2022 | seekingalpha.com
Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial
September 28, 2022 | realmoney.thestreet.com
Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game
September 28, 2022 | msn.com
Is This the First Alzheimer's Drug to Actually Work?
September 28, 2022 | investing.com
Eisai says Alzheimer's drug succeeds in slowing cognitive decline
September 28, 2022 | seekingalpha.com
Biogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trial
September 27, 2022 | barrons.com
Pharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer’s Drug Trial
September 24, 2022 | fool.com
Eisai Co., Ltd (ADR) (OTC: ESALY)
September 23, 2022 | barrons.com
Can We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues.
See More Headlines
Receive ESALY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

ESALY Company Calendar

Last Earnings
8/04/2021
Today
12/07/2022
Fiscal Year End
3/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ESALY
CUSIP
N/A
CIK
948406
Web
www.eisai.co.jp
Phone
(133) 817-3700
Fax
813-3811-6032
Employees
11,322
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
$0.87
Trailing P/E Ratio
80.91
Forward P/E Ratio
46.62
P/E Growth
3.67
Net Income
$426.79 million
Net Margins
4.11%
Pretax Margin
7.20%
Return on Equity
3.79%
Return on Assets
2.43%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
2.06
Quick Ratio
1.71

Sales & Book Value

Annual Sales
$6.74 billion
Price / Sales
3.00
Cash Flow
$2.59 per share
Price / Cash Flow
27.17
Book Value
$23.94 per share
Price / Book
2.94

Miscellaneous

Outstanding Shares
286,770,000
Free Float
N/A
Market Cap
$20.19 billion
Optionable
Not Optionable
Beta
0.29

Key Executives

  • Mr. Haruo Naito (Age 75)
    CEO, Representative Corp. Officer & Director
    Comp: $805.08k
  • Mr. Gary Hendler (Age 56)
    Sr. VP & Pres of EMEA Region
    Comp: $956.46k
  • Dr. Lynn D. Kramer FAAN (Age 72)
    M.D., VP & Chief Clinical Officer - Alzheimer's Disease and Brain Health
    Comp: $818.84k
  • Ms. Yanhui Feng (Age 50)
    Sr. VP
    Comp: $756.91k
  • Dr. Nadeem Sarwar Ph.D.
    Pres
  • Mr. Tatsuyuki Yasuno (Age 54)
    Sr. VP, CFO & Chief IR Officer
  • Mr. Kenta Takahashi (Age 63)
    Exec. VP, Gen. Counsel & Intellectual Property Internal Audit
  • Mr. Yosuke Akita (Age 57)
    VP, Chief Compliance Officer & Chief Information Security Officer
  • Ms. Sayoko Sasaki (Age 54)
    VP of Corp. Communications & ESG
  • Mr. Teruyuki Masaka (Age 44)
    VP & Chief HR Officer

Key Competitors

View All Competitors













ESALY Stock - Frequently Asked Questions

Should I buy or sell Eisai stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ESALY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESALY, but not buy additional shares or sell existing shares.
View ESALY analyst ratings or view top-rated stocks.

How have ESALY shares performed in 2022?

Eisai's stock was trading at $56.82 on January 1st, 2022. Since then, ESALY stock has increased by 23.9% and is now trading at $70.39.
View the best growth stocks for 2022 here.

Are investors shorting Eisai?

Eisai saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 50,400 shares, a decrease of 20.1% from the October 15th total of 63,100 shares. Based on an average daily trading volume, of 58,100 shares, the short-interest ratio is currently 0.9 days.
View Eisai's Short Interest.

How were Eisai's earnings last quarter?

Eisai Co., Ltd. (OTCMKTS:ESALY) issued its quarterly earnings results on Wednesday, August, 4th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. The business had revenue of $1.82 billion for the quarter. Eisai had a trailing twelve-month return on equity of 3.79% and a net margin of 4.11%.

Is Eisai a good dividend stock?

Eisai (OTCMKTS:ESALY) pays an annual dividend of $0.88 per share and currently has a dividend yield of 1.21%. The dividend payout ratio is 101.15%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ESALY will have a dividend payout ratio of 73.33% next year. This indicates that the company will be able to sustain or increase its dividend.

What guidance has Eisai issued on next quarter's earnings?

Eisai issued an update on its FY 2023 earnings guidance on Monday, November, 21st. The company provided earnings per share (EPS) guidance of $1.38-$1.38 for the period. The company issued revenue guidance of $5.32 billion-$5.32 billion.

What is Eisai's stock symbol?

Eisai trades on the OTCMKTS under the ticker symbol "ESALY."

How do I buy shares of Eisai?

Shares of ESALY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eisai's stock price today?

One share of ESALY stock can currently be purchased for approximately $70.39.

How much money does Eisai make?

Eisai (OTCMKTS:ESALY) has a market capitalization of $20.19 billion and generates $6.74 billion in revenue each year. The company earns $426.79 million in net income (profit) each year or $0.87 on an earnings per share basis.

How many employees does Eisai have?

The company employs 11,322 workers across the globe.

How can I contact Eisai?

Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The official website for the company is www.eisai.co.jp. The company can be reached via phone at (133) 817-3700 or via fax at 813-3811-6032.

This page (OTCMKTS:ESALY) was last updated on 12/7/2022 by MarketBeat.com Staff